ArticleBlood2024

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.

Inge van Outersterp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.